These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

843 related items for PubMed ID: 23181944

  • 1. Ivabradine: in adults with chronic heart failure with reduced left ventricular ejection fraction.
    Perry CM.
    Am J Cardiovasc Drugs; 2012 Dec 01; 12(6):415-26. PubMed ID: 23181944
    [Abstract] [Full Text] [Related]

  • 2. Ivabradine: Current and Future Treatment of Heart Failure.
    Thorup L, Simonsen U, Grimm D, Hedegaard ER.
    Basic Clin Pharmacol Toxicol; 2017 Aug 01; 121(2):89-97. PubMed ID: 28371247
    [Abstract] [Full Text] [Related]

  • 3. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study.
    Swedberg K, Komajda M, Böhm M, Borer J, Robertson M, Tavazzi L, Ford I, SHIFT Investigators.
    J Am Coll Cardiol; 2012 May 29; 59(22):1938-45. PubMed ID: 22617188
    [Abstract] [Full Text] [Related]

  • 4. Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I(f) Inhibitor Ivabradine Trial (SHIFT).
    Swedberg K, Komajda M, Böhm M, Borer JS, Ford I, Tavazzi L.
    Eur J Heart Fail; 2010 Jan 29; 12(1):75-81. PubMed ID: 19892778
    [Abstract] [Full Text] [Related]

  • 5. Selective and specific I(f) inhibition with ivabradine: new perspectives for the treatment of cardiovascular disease.
    Ferrari R, Ceconi C.
    Expert Rev Cardiovasc Ther; 2011 Aug 29; 9(8):959-73. PubMed ID: 21878041
    [Abstract] [Full Text] [Related]

  • 6. Limited role for ivabradine in the treatment of chronic heart failure.
    Cullington D, Goode KM, Cleland JG, Clark AL.
    Heart; 2011 Dec 29; 97(23):1961-6. PubMed ID: 21917660
    [Abstract] [Full Text] [Related]

  • 7. Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the I(f) inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) study.
    Fox K, Ferrari R, Tendera M, Steg PG, Ford I, BEAUTIFUL Steering Committee.
    Am Heart J; 2006 Nov 29; 152(5):860-6. PubMed ID: 17070146
    [Abstract] [Full Text] [Related]

  • 8. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial.
    Fox K, Ford I, Steg PG, Tendera M, Ferrari R, BEAUTIFUL Investigators.
    Lancet; 2008 Sep 06; 372(9641):807-16. PubMed ID: 18757088
    [Abstract] [Full Text] [Related]

  • 9. Impact of a pure reduction in heart rate for the treatment of left ventricular dysfunction: clinical benefits of ivabradine in the BEAUTIFUL trial.
    Danchin N.
    Therapie; 2009 Sep 06; 64(2):111-4. PubMed ID: 19664404
    [Abstract] [Full Text] [Related]

  • 10. Heart rate reduction by I(f)-channel inhibition and its potential role in heart failure with reduced and preserved ejection fraction.
    Reil JC, Reil GH, Böhm M.
    Trends Cardiovasc Med; 2009 Jul 06; 19(5):152-7. PubMed ID: 20005474
    [Abstract] [Full Text] [Related]

  • 11. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial.
    Böhm M, Swedberg K, Komajda M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L, SHIFT Investigators.
    Lancet; 2010 Sep 11; 376(9744):886-94. PubMed ID: 20801495
    [Abstract] [Full Text] [Related]

  • 12. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study.
    Swedberg K, Komajda M, Böhm M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L, SHIFT Investigators.
    Lancet; 2010 Sep 11; 376(9744):875-85. PubMed ID: 20801500
    [Abstract] [Full Text] [Related]

  • 13. I(f) current inhibitor ivabradine in patients with idiopathic dilated cardiomyopathy: Impact on the exercise tolerance and quality of life.
    Abdel-Salam Z, Rayan M, Saleh A, Abdel-Barr MG, Hussain M, Nammas W.
    Cardiol J; 2015 Sep 11; 22(2):227-32. PubMed ID: 25179314
    [Abstract] [Full Text] [Related]

  • 14. Ivabradine, a novel medication for treatment of heart failure with reduced ejection fraction.
    Foster JL, Bobadilla RV.
    J Am Assoc Nurse Pract; 2016 Nov 11; 28(11):576-582. PubMed ID: 27215699
    [Abstract] [Full Text] [Related]

  • 15. [Efficacy and safety analysis of ivabradine hydrochloride treatment of Chinese patients with chronic heart failure: subgroup analysis of Chinese patients in the SHIFT study].
    Hu DY, Huang DJ, Yuan ZY, Zhao RP, Yan XW, Wang MH, Chinese Investigators of SHIFT Study.
    Zhonghua Xin Xue Guan Bing Za Zhi; 2017 Mar 24; 45(3):190-197. PubMed ID: 28316174
    [Abstract] [Full Text] [Related]

  • 16. Heart rate reduction after heart transplantation with beta-blocker versus the selective If channel antagonist ivabradine.
    Doesch AO, Celik S, Ehlermann P, Frankenstein L, Zehelein J, Koch A, Katus HA, Dengler TJ.
    Transplantation; 2007 Oct 27; 84(8):988-96. PubMed ID: 17989604
    [Abstract] [Full Text] [Related]

  • 17. Rate control with ivabradine: angina pectoris and beyond.
    Parakh N, Bhargava B.
    Am J Cardiovasc Drugs; 2011 Oct 27; 11(1):1-12. PubMed ID: 21090826
    [Abstract] [Full Text] [Related]

  • 18. Influence of background treatment with mineralocorticoid receptor antagonists on ivabradine's effects in patients with chronic heart failure.
    Komajda M, Böhm M, Borer J, Ford I, Krum H, Tase A, Tavazzi L, Swedberg K.
    Eur J Heart Fail; 2013 Jan 27; 15(1):79-84. PubMed ID: 22892123
    [Abstract] [Full Text] [Related]

  • 19. Effect of ivabradine in patients with left-ventricular systolic dysfunction: a pooled analysis of individual patient data from the BEAUTIFUL and SHIFT trials.
    Fox K, Komajda M, Ford I, Robertson M, Böhm M, Borer JS, Steg PG, Tavazzi L, Tendera M, Ferrari R, Swedberg K.
    Eur Heart J; 2013 Aug 27; 34(29):2263-70. PubMed ID: 23536611
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure (from the SHIFT study).
    Borer JS, Böhm M, Ford I, Robertson M, Komajda M, Tavazzi L, Swedberg K, SHIFT Investigators.
    Am J Cardiol; 2014 Feb 01; 113(3):497-503. PubMed ID: 24332674
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 43.